# Sirtuin Activation and Metformin: Insights from Aging Mice Studies

Canonical source: https://retacompare.com/research/sirtuin-activation-and-metformin-insights-from-aging-mice-studies

Sinclair Lab Research · 2020-10-15


    Combining a high dose of metformin with the sirtuin activator SRT1720 can reduce lifespan in aged mice. This study, conducted by researchers including Prof. David Sinclair, investigates the effects of these compounds on longevity in a high-fat diet context. Understanding the interactions between these interventions is crucial for future aging research.

 What this study examined

The study examined the effects of SRT1720, a sirtuin1-activator, and metformin (MET), an antidiabetic drug, on aging mice. Specifically, 56-week-old C57BL/6J male mice were fed a high-fat diet (HFD) with either SRT1720, a high dose of MET, or a combination of both. The primary outcomes included survival, body weight, food consumption, body composition, and rotarod performance, providing a comprehensive view of the health and longevity impacts of these treatments.

 Why this matters for longevity research

This research is significant as it challenges the assumption that combining different longevity-promoting compounds will yield additive benefits. The findings suggest that the combination of SRT1720 and MET may be detrimental to survival, raising important questions about the safety and efficacy of using multiple interventions in aging populations. Understanding these interactions is vital for optimizing healthspan and lifespan strategies.

 Key findings

Mice treated with metformin alone did not show improved longevity.

The combination of metformin and SRT1720 significantly reduced lifespan.

All groups consumed similar amounts of food, indicating that caloric intake did not influence the outcomes.

Mice receiving metformin or the combination treatment exhibited a sharp reduction in body weight.

Those treated with SRT1720 and metformin had lower body fat percentages.

Mice on the combination treatment performed better on the rotarod test compared to controls.

The study highlights the need for careful evaluation of risk-benefit profiles when combining lifespan-extending drugs.

 The science behind it

The mechanisms underlying the effects of metformin and SRT1720 involve key biological pathways associated with aging, such as the NAD+/sirtuin axis. Sirtuins, particularly SIRT1, are implicated in regulating metabolic processes and cellular stress responses. Metformin is known to activate AMPK, a crucial energy sensor that influences autophagy and metabolism. The interaction between these pathways is complex, and the adverse outcomes observed in this study suggest that the combined effects may disrupt normal physiological processes, warranting further investigation into their mechanisms.

 How it fits into the longevity field

This study contributes to the growing body of literature on the effects of pharmacological interventions on aging. Previous research has shown that both metformin and sirtuin activators can confer health benefits when used individually. However, this study emphasizes the importance of understanding potential negative interactions when these agents are combined. It aligns with ongoing investigations into other interventions, such as caloric restriction and various compounds targeting the mTOR pathway, which also aim to extend healthspan and lifespan.

 Practical takeaways

Researchers and informed readers should consider the implications of this study when exploring combination therapies for aging. The findings underscore the necessity for systematic evaluations of risk and benefits when combining different longevity-promoting drugs, particularly in older populations. Future research should focus on elucidating the mechanisms behind these interactions to develop safer and more effective strategies for extending healthspan.

 FAQ

 What is the role of sirtuins in aging?

Sirtuins are proteins that play a crucial role in regulating cellular processes related to aging, including metabolism, DNA repair, and stress responses.

 How does metformin affect lifespan?

Metformin has been shown to improve healthspan and has potential lifespan-extending properties, but its effects can vary depending on the context and dosage.

 What are the implications of combining longevity drugs?

The study highlights that combining different longevity-promoting drugs may not always yield positive outcomes, emphasizing the need for careful evaluation of such combinations.

 Source: PubMed · J Gerontol A Biol Sci Med Sci · published 2020-10-15.

## Sources

- PubMed · J Gerontol A Biol Sci Med Sci: https://pubmed.ncbi.nlm.nih.gov/32556267/